PROBIOCAL: Effects of Probiotics and Calcium Supplementation on Growth, Development, and Metabolic Parameters

Sponsor
Indonesia University (Other)
Overall Status
Completed
CT.gov ID
NCT04046289
Collaborator
SEAMEO Regional Centre for Food and Nutrition (Other), Wageningen University (Other)
238
1
5.3
45.3

Study Details

Study Description

Brief Summary

Stunting is still a major problem in developing countries, including Indonesia, and has been associated with impaired development. Stunted children have also a higher risk of metabolic syndrome in adulthood. The gut microbiota, as a part of intestinal integrity, may promote intake of nutrient during childhood. Probiotics supplementation may optimize the balance of gut microbiota and further improve child growth during the window period. Furthermore, calcium could also improve child growth by increasing the resistance to intestinal infection. However, the long-term effects of gut microbiota optimization during childhood using probiotics and calcium on growth, development, and the metabolic condition has not widely studied.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Low Calcium Milk
  • Dietary Supplement: Regular Calcium Milk
  • Dietary Supplement: Probiotic 1
  • Dietary Supplement: Probiotic 2

Detailed Description

This study was a 10-year follow-up study of randomized controlled trials of 6-month probiotics and calcium supplementation of Lactobacillus reuteri DSM 17938 or Lactobacillus casei CRL 431 in children aged 1-6 years (n=494) living in urban low socioeconomic communities of East Jakarta in 2007-2008. We re-enrolled the subjects to assess the long-term effects of probiotics and calcium supplementation on growth, development, and metabolic parameters at the age of 11-17 years.

Healthy children (n = 238) were included in this follow-up study. Each subject previously assigned to one intervention group: low-lactose milk with a low calcium content (LC = 53), a regular calcium content (RC = 70), regular calcium with L. reuteri DSM 17938 (n = 55), and regular calcium with L. casei CRL 431 (n = 60).

Anthropometric measurements were performed by measuring the weight and height of the subjects, and further combining the results to report BMI-for-age z-score. Height was also plotted to the chart of the World Health Organization (WHO) Child Growth Standards. Gut integrity was assessed with the lactulose-mannitol ratio using high-performance liquid chromatography (HPLC) method. Cognitive function, symptoms related to depression, behaviour, and serum brain-derived neurotrophic factors (BDNF) of the adolescents were evaluated used to investigate the effects of supplementation on development. We quantified lipid profile and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) as metabolic parameters using the vein blood sample. The metabolic parameters were measured in at least three groups of intervention.

Study Design

Study Type:
Observational
Actual Enrollment :
238 participants
Observational Model:
Cohort
Time Perspective:
Cross-Sectional
Official Title:
Effects of 6-Month Probiotics and Calcium Supplementation During Childhood on Growth, Development, and Metabolic Parameters in Adolescents: A 10-Year Follow-up Study
Actual Study Start Date :
Jan 26, 2019
Actual Primary Completion Date :
Mar 3, 2019
Actual Study Completion Date :
Jul 5, 2019

Arms and Interventions

Arm Intervention/Treatment
Low Calcium

low calcium milk of 180 ml, twice daily for 24 weeks

Dietary Supplement: Low Calcium Milk
50 mg calcium/day

Regular Calcium

regular calcium milk of 180 ml, twice daily for 24 weeks

Dietary Supplement: Regular Calcium Milk
400 mg/day

Probiotic 1

regular calcium milk of 180 ml + probiotic, twice daily for 24 weeks

Dietary Supplement: Probiotic 1
regular calcium milk + probiotic

Probiotic 2

regular calcium milk of 180 ml + probiotic, twice daily for 24 weeks

Dietary Supplement: Probiotic 2
regular calcium milk + probiotic

Outcome Measures

Primary Outcome Measures

  1. Child's linear growth the age of 11-17 years [January - March 2019]

    Height-for-age z-score based on the WHO Child Growth Standards.

  2. Child's height at the age of 11-17 years [January - March 2019]

    Height in meters.

  3. Child's weight at the age of 11-17 years [January - March 2019]

    Weight in kilograms.

  4. Child's nutritional status at the age of 11-17 years [January - March 2019]

    BMI-for-age z-score based on the WHO Child Growth Standards. BMI was calculated from height and weight measurement.

Secondary Outcome Measures

  1. Gut integrity at the age of 11-17 years [January - March 2019]

    Lactulose-mannitol ratio was calculated by dividing percent excretion of lactulose with percent excretion of mannitol.

  2. Cognitive function assessed using Raven's Progressive Matrices at the age of 11-17 years [January - March 2019]

    Raven's Progressive Matrices (RPM) was administered by psychologists. Raw score of RPM was used to evaluate adolescents' cognition.

  3. Symptoms related to depression assessed using Children Depression Inventory at the age of 11-17 years [January - March 2019]

    Children Depression Inventory (CDI) was a self-assigned questionnaire and the total score of CDI with a range between 0 - 54 (lower, better) was used to evaluate the symptoms related to depression among adolescents.

  4. Behaviour assessed using Strength and Difficulties Questionnaire at the age of 11-17 years [January - March 2019]

    Strength and Difficulties Questionnaire (SDQ) was a self-assigned questionnaire and the total difficulties score of SDQ with a range between 0 - 50 (lower, better) was used to evaluate the behaviour among adolescents.

  5. Serum BDNF at the age of 11-17 years [January - March 2019]

    Serum BDNF in pg/ml was quantified using ELISA method

  6. Triglyceride level at the age of 11-17 years [January - March 2019]

    Triglyceride level in milligrams per decilitre.

  7. High-density lipoprotein level at the age of 11-17 years [January - March 2019]

    High-density lipoprotein level in milligrams per decilitre.

  8. Low-density lipoprotein level at the age of 11-17 years [January - March 2019]

    Low-density lipoprotein level in milligrams per decilitre.

  9. Fasting insulin level at the age of 11-17 years [January - March 2019]

    Fasting insulin level in μU per millilitre

  10. Fasting glucose level at the age of 11-17 years [January - March 2019]

    Fasting glucose level in milligrams per decilitre.

  11. HOMA-IR at the age of 11-17 years [January - March 2019]

    HOMA-IR was quantified by multiplying fasting insulin level with fasting glucose level.

Eligibility Criteria

Criteria

Ages Eligible for Study:
11 Years to 17 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria at the previous clinical trial:
  • Apparently healthy children aged 1-6 years, with emphasize on aged 2-5 years, living permanently in low socio-economic urban areas of East Jakarta for at least six months

  • Parents are willing to sign the informed consent and give the supplements to the children for six months

  • Capable and willing to drink liquid milk with a straw (acceptance to be tested at the screening by providing a sample drink and placebo straw to be consumed under supervision for two days)

Exclusion Criteria at the previous clinical trial:
  • Calcium intake exceeding 75% of the Recommended Dietary Allowance (RDA) for calcium (<375 mg/d) based on a Food Frequency Questionnaire

  • Currently breastfed children

  • Siblings of already included children that are living in the same household, except if it is a twin sibling

  • Severely malnourished with or without edema (weight-for-height Z-score of <-3.00 SD)

  • Symptoms of chronic/congenital diseases and disabilities, suspected Tuberculosis by clinical examination, and/or history of allergic disease.

  • Taking (any) antibiotics during 2 weeks prior to the start of the study (children will be included after 3 weeks of last antibiotic intake

  • Participation in another clinical trial at the same time or 2 months prior to the start of this study

  • Both mothers and other caregivers present in the family are illiterate

Inclusion criteria of follow-up study:
  • Healthy adolescent participated in the previous trial study willing to take part in the follow-up study
Exclusion criteria of follow-up study:
  • History of type 1 diabetes

  • Taking the cholesterol-lowering drug, an anti-diabetic drug, or oral corticosteroid for more than 2 consecutive weeks in the last 3 months

  • Pregnant

Contacts and Locations

Locations

Site City State Country Postal Code
1 Human Nutrition Research Center, Indonesian Medical Education Research Institute; and Department of Nutrition, Faculty of Medicine, Universitas Indonesia Jakarta Pusat DKI Jakarta Indonesia 13420

Sponsors and Collaborators

  • Indonesia University
  • SEAMEO Regional Centre for Food and Nutrition
  • Wageningen University

Investigators

  • Principal Investigator: Rina Agustina, PhD, HNRC IMERI; Department of Nutrition, Faculty of Medicine, Universitas Indonesia

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Rina Agustina, Principal Investigator, Indonesia University
ClinicalTrials.gov Identifier:
NCT04046289
Other Study ID Numbers:
  • probiocal
First Posted:
Aug 6, 2019
Last Update Posted:
Aug 7, 2019
Last Verified:
Aug 1, 2019
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 7, 2019